Vir Biotechnology to present BMI impact on ALT normalization at EASL2026 Phase 2 SOLSTICE analysis

Vir Biotechnology to present BMI impact on ALT normalization at EASL2026 Phase 2 SOLSTICE analysis
Vir Biotechnology unveils EASL2026 study

Vir Biotechnology is set to present new findings from its Phase 2 SOLSTICE Week 48 subgroup analysis, focusing on the impact of body mass index (BMI) on ALT normalization in participants with chronic hepatitis delta. The session will take place during EASL2026 on May 29, from 4:15 p.m. to 5 p.m. CET.

This poster presentation aims to uncover new research insights that could inform treatment approaches for chronic hepatitis delta, a challenging liver disease. Attendees can expect detailed data on how BMI may affect therapeutic outcomes as measured by ALT normalization. Further information and supporting material are available through the company's provided online resources.

Vir Biotechnology recently announced its Q1 2026 financial results and offered a corporate update during a scheduled investor conference call. Earlier this year, CEO Marianne De Backer participated in a live fireside chat at the Bank of America Securities 2026 Healthcare Conference. The company continues to share research and operational updates with investors and the medical community.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.